### **Overview** Valiant Organics Limited is a leading Indian manufacturer of specialty chemicals and pharmaceutical intermediates, headquartered in Mumbai. Established in 1984 as Valiant Chemical Corporation, the company has evolved into one of the largest global manufacturers of **chlorophenol derivatives** and a dominant domestic player in key chemical segments. As a member of the **Aarti Group**, it leverages backward integration, technical expertise, and strategic acquisitions to strengthen its position in the global specialty chemicals market. The company operates **six integrated manufacturing units** across five strategic locations in Gujarat and Maharashtra—Sarigam, Tarapur, Vapi, Jhagadia (Units 1 & 2), and Ahmedabad—with a total installed capacity of **70,000 tonnes per annum (TPA)**. Its facilities are situated near major western Indian ports, enabling efficient logistics and export-oriented operations. --- ### **Core Competencies & Key Processes** Valiant Organics specializes in advanced chemical processes, including: - **Chlorination** - **Hydrogenation** - **Ammonolysis** - **Acetylation** - **Sulphonation** - **Methoxylation** These chemistries form the foundation for a diversified product portfolio focused on **high-demand, low-supply specialty chemicals**, many of which were historically imported into India. The company positions itself as a key **import substitute**, especially in the pharmaceutical and agrochemical sectors. --- ### **Key Products** The company's primary product portfolio includes: - **Chlorophenol Derivatives**: - Para Chlorophenol (PCP), Ortho Chlorophenol (OCP), 2,4-DCP, 2,6-DCP, 2,4,6-TCP - **Ammonolysis-Based Chemicals**: - Para Nitro Aniline (PNA), Ortho Chloro Para Nitro Aniline - **Hydrogenation Products**: - Ortho Anisidine (OA), Para Anisidine (PA), IPPCA, Meta Chloro Aniline, Ortho Amino Phenol (OAP), Para Amino Phenol (PAP) - **Others**: 6-Acetyl Ortho Aminophenol Para Sulfonic Acid, OT5SA, 4B Acid Valiant is among the **first Indian producers of Para Amino Phenol (PAP)**, a critical intermediate in paracetamol synthesis, and one of the few commercial manufacturers of **OA and PA** in the country. --- ### **Global Market Position** - **Chlorophenols**: - One of the **largest global manufacturers**, holding **~25% of the global market share**. - The **only Indian producer** of chlorophenol derivatives. - **PNA**: - One of the **largest domestic producers** with strong market leadership. - **PAP**: - Domestic pioneer with a **12,000 MTPA plant** at Jhagadia (Unit 2), established in FY 2020–21. - Supplies ~85% internally to **Valiant Laboratories Ltd.** (group company) for paracetamol manufacturing. Valiant’s products serve major industries including **pharmaceuticals, agrochemicals, dyes & pigments, cosmetics, rubber, and veterinary drugs**, with a diversified global customer base across **North America, Europe, Japan, and China**. --- ### **Manufacturing Infrastructure & Capacity** | **Location** | **Process & Capacity** | |-------------------|------------------------| | **Sarigam** | Chlorination – 18,000 MTPA | | **Tarapur & Vapi** | Ammonolysis – 16,600 MTPA combined (10,000 + 6,600 MTPA) | | **Jhagadia Unit 1**| Hydrogenation & Methoxylation – 28,800 MTPA | | **Jhagadia Unit 2**| Hydrogenation (PAP) – 12,000 MTPA | | **Ahmedabad** | Acetylation & Sulphonation – 1,800 MTPA | Each site is specialized for process efficiency and product purity, with **five zero liquid discharge (ZLD) plants** and automated **Distributed Control Systems (DCS)** ensuring environmental compliance, safety, and operational excellence. --- ### **Revenue Streams & Business Model** - **Revenue Mix (FY22–23)**: - **Hydrogenation**: ~45% - **Ammonolysis**: ~29% - **Chlorination**: ~20% - **Customer Base**: Primarily **B2B**, serving multinational corporations and large Indian manufacturers (e.g., Anupam Rasayan, Lanxess, Clariant, Kisco). - **Geographic Sales Mix (FY22–23)**: - Domestic: **94%** (~₹853 crore) - Export: **6%** (~₹59 crore) Exports are expected to grow significantly due to the **"China +1" global supply chain shift**. - **Revenue Outlook (FY25)**: - Target revenue of **₹900–1,000 crore**, representing ~40% year-on-year growth. - Growth to be driven by **PAP, OAP, expanded chlorophenol output, and pharma intermediates**. --- ### **Innovation, Integration & Growth Strategy** - **Backward Integration**: - Secure supply of key raw materials (e.g., **PNCB** via Aarti Industries) for PAP and PNA. - In-house production of **Ortho Nitro Anisole (ONA)** and **Para Nitro Anisole (PNA)** for internal use. - **Forward Integration**: - Production of high-margin intermediates like **PAP and OAP**; plans for **paracetamol and API manufacturing**. - **Recent Projects**: - Commissioning of **multi-purpose Pharma Intermediates Plant** (20 MTPA) producing N-1 and N-2 for API use. - Development of **Ortho Amino Phenol (OAP)** plant (100 MTPA), with trial runs completed and commercial launch expected by end-FY23. - **R&D & Automation**: - State-of-the-art in-house laboratory with skilled chemists. - Transition of distillation to **continuous mode**, improving yield and reducing energy. - DCS implementation across plants for **quality, safety, and efficiency**. --- ### **Financial & Market Information** - **Listed on**: BSE & NSE (moved from SME platform in 2016 to main board in 2020) - **Market Capitalization**: - ₹730 crores (as of March 31, 2025) - **Ownership Structure**: Part of **Aarti Group**, a diversified chemical conglomerate (Aarti Industries, Aarti Drugs, Aarti Surfactants). --- ### **Strategic Advantages** 1. **Integrated, Multi-Process Platform**: Enables flexible, multi-product manufacturing and contract/job work services. 2. **Supply Chain Security**: Backward integration and group synergies ensure raw material availability. 3. **Export Potential**: Rising global demand for Indian chemical alternatives due to **China+1 strategy**, Rupee depreciation, and regulatory pressures in China. 4. **Sustainability & Compliance**: ZLD plants and automated controls enhance ESG credentials. 5. **Long-Term Contracts**: ~60% of business secured via multi-year contracts, providing revenue stability. --- ### **Recent Developments & Outlook (2024–2025)** - **PAP ramp-up**: Achieved stabilization in quality and production; targeting **US and EU markets** post-standardization. - **New Molecule in Chlorination**: Niche, **margin-accretive product** launched in late 2023; volume production underway. - **Capacity Utilization & Mix**: Focus on optimizing product mix and increasing capacity utilization. - **Capital Expenditure**: ~₹100 crores invested in 3 new projects at Jhagadia, including pharma intermediates and plant upgrades. - **Land Bank**: 68,000 sq. m. in Gujarat (Koliyad/Sayakha/Dahej) for future expansion into **pharmaceuticals and specialty chemicals**.